Lipocine Inc. gets Health Canada approval for TLANDO
- Health Canada approved TLANDO for testosterone replacement therapy in adult males on 2026-10-07.
- Verity Pharma has exclusive commercial rights to TLANDO in North America.
Every EDGAR filing for Lipocine Inc. (LPCN), newest first, with AI summaries and stories.
Next: earnings expected ~Nov 6 · 10-Q expected ~Nov 9 (deadline Nov 16)
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
John W. Higuchi, insider filing for LPCN
John W. Higuchi
John W. Higuchi, insider filing for LPCN
John W. Higuchi, reporting
Ownership stake disclosure by Squadron Capital Management LLC (amended)
Squadron Capital Management LLC, filed by
Michael Grissinger, insider filing for LPCN
Michael Grissinger, reporting
Mahesh V. Patel, insider filing for LPCN
Mahesh Patel V., reporting
Richard Dana Ono, insider filing for LPCN
Richard Dana Ono, reporting
Ownership stake disclosure by Ikarian Capital, LLC
Ikarian Capital, LLC, filed by
Ownership stake disclosure by Squadron Capital Management LLC (amended)
Squadron Capital Management LLC, filed by
John W. Higuchi, insider filing for LPCN
John W. Higuchi, reporting
John W. Higuchi, insider filing for LPCN
John W. Higuchi, reporting
Mahesh V. Patel, insider filing for LPCN
Mahesh Patel V., reporting
Ownership stake disclosure by Squadron Capital Management LLC (amended)
Squadron Capital Management LLC, filed by
Mahesh V. Patel, insider filing for LPCN
Mahesh Patel V., reporting
Ownership stake disclosure by Squadron Capital Management LLC
Squadron Capital Management LLC, filed by